August 17, 2020

Teva, Cipla Appear to Settle Generic Delay Suit Over Sensipar

Cipla Ltd. dropped an antitrust lawsuit against Teva Pharmaceutical Industries Ltd., following an apparent settlement of claims in Delaware federal court that Teva stopped selling its generic version of Amgen Inc.'s blockbuster calcium reducer Sensipar because of an anti-competitive patent deal.

Related Services & Industries

Stay Up To Date With Our Insights

See how we use a multidisciplinary, integrated approach to meet our clients' needs.